John Patrick Shannon Jr. - 11 Nov 2021 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
President and Chief Operating Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
11 Nov 2021
Net transactions value
+$209,500
Form type
4
Filing time
12 Nov 2021, 16:12:51 UTC
Previous filing
05 Oct 2021
Next filing
05 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $83,500 +40,000 +15% $2.09 303,829 11 Nov 2021 Direct F1
transaction XERS Common Stock Purchase $126,000 +60,000 +20% $2.10 363,829 12 Nov 2021 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.08 to $2.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.09 to $2.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Remarks:

President and Chief Operating Officer